ARCT vs VRTX: Which Stock is Better?
Side-by-side comparison of Arcturus Therapeutics Holdings Inc and Vertex Pharmaceuticals Inc in 2026
ARCT
Arcturus Therapeutics Holdings Inc
$6.39
VRTX
Vertex Pharmaceuticals Inc
$462.49
Key Metrics Comparison
| Metric | ARCT | VRTX | Winner |
|---|---|---|---|
| Market Cap | $181.62M | $118.39B | VRTX |
| P/E Ratio | N/A | 30.40 | VRTX |
| EPS (TTM) | $N/A | $15.33 | VRTX |
| Revenue Growth | -0.7% | 0.1% | VRTX |
| Gross Margin | -36.8% | 53.7% | VRTX |
Analyze ARCT
Full quant analysis
Analyze VRTX
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ARCT or VRTX a better investment?
Comparing ARCT and VRTX: Arcturus Therapeutics Holdings Inc has a market cap of $181.62M while Vertex Pharmaceuticals Inc has $118.39B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ARCT and VRTX?
ARCT (Arcturus Therapeutics Holdings Inc) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ARCT or VRTX?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ARCT or VRTX?
VRTX has higher revenue growth at 0.1% vs -0.7% for ARCT.
Which company is more profitable: ARCT or VRTX?
Vertex Pharmaceuticals Inc (VRTX) has higher gross margins at 53.7% compared to -36.8% for ARCT.
Which is the larger company: ARCT or VRTX?
Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $118.39B compared to $181.62M for ARCT.
Should I buy ARCT or VRTX in 2026?
Both ARCT and VRTX have investment merit. ARCT trades at $6.39 while VRTX trades at $462.49. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ARCT and VRTX stock?
Key differences: Market Cap ($181.62M vs $118.39B), P/E Ratio (N/A vs 30.4x), Revenue Growth (-0.7% vs 0.1%), Gross Margin (-36.8% vs 53.7%).